PortalPublikationenSerum midkine correlates with tumor progression and imatinib...

Serum midkine correlates with tumor progression and imatinib response in gastrointestinal stromal tumors.

Standard

Serum midkine correlates with tumor progression and imatinib response in gastrointestinal stromal tumors. / Rawnaq, Tamina; Kunkel, Miriam; Bachmann, Kai; Simon, Ronald; Zander, Hilke; Brandl, Stephan; Sauter, Guido; Izbicki, Jakob R.; Kaifi, Jussuf.

in: ANN SURG ONCOL, Jahrgang 18, Nr. 2, 2, 2011, S. 559-565.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Rawnaq, T, Kunkel, M, Bachmann, K, Simon, R, Zander, H, Brandl, S, Sauter, G, Izbicki, JR & Kaifi, J 2011, 'Serum midkine correlates with tumor progression and imatinib response in gastrointestinal stromal tumors.', ANN SURG ONCOL, Jg. 18, Nr. 2, 2, S. 559-565. <http://www.ncbi.nlm.nih.gov/pubmed/20589434?dopt=Citation>

APA

Rawnaq, T., Kunkel, M., Bachmann, K., Simon, R., Zander, H., Brandl, S., Sauter, G., Izbicki, J. R., & Kaifi, J. (2011). Serum midkine correlates with tumor progression and imatinib response in gastrointestinal stromal tumors. ANN SURG ONCOL, 18(2), 559-565. [2]. http://www.ncbi.nlm.nih.gov/pubmed/20589434?dopt=Citation

Vancouver

Rawnaq T, Kunkel M, Bachmann K, Simon R, Zander H, Brandl S et al. Serum midkine correlates with tumor progression and imatinib response in gastrointestinal stromal tumors. ANN SURG ONCOL. 2011;18(2):559-565. 2.

Bibtex

@article{a592efbe52d04ed38553da0e42f537ea,
title = "Serum midkine correlates with tumor progression and imatinib response in gastrointestinal stromal tumors.",
abstract = "A previous study identified midkine (MK) expression in primary gastrointestinal stromal tumor (GIST) as a prognostic marker. The aim of the current study was to compare serum midkine (S-MK) concentrations of GIST patients with those of healthy controls and to determine if MK can serve as a prognostic serum marker for these patients.",
author = "Tamina Rawnaq and Miriam Kunkel and Kai Bachmann and Ronald Simon and Hilke Zander and Stephan Brandl and Guido Sauter and Izbicki, {Jakob R.} and Jussuf Kaifi",
year = "2011",
language = "English",
volume = "18",
pages = "559--565",
journal = "ANN SURG ONCOL",
issn = "1068-9265",
publisher = "Springer New York",
number = "2",

}

RIS

TY - JOUR

T1 - Serum midkine correlates with tumor progression and imatinib response in gastrointestinal stromal tumors.

AU - Rawnaq, Tamina

AU - Kunkel, Miriam

AU - Bachmann, Kai

AU - Simon, Ronald

AU - Zander, Hilke

AU - Brandl, Stephan

AU - Sauter, Guido

AU - Izbicki, Jakob R.

AU - Kaifi, Jussuf

PY - 2011

Y1 - 2011

N2 - A previous study identified midkine (MK) expression in primary gastrointestinal stromal tumor (GIST) as a prognostic marker. The aim of the current study was to compare serum midkine (S-MK) concentrations of GIST patients with those of healthy controls and to determine if MK can serve as a prognostic serum marker for these patients.

AB - A previous study identified midkine (MK) expression in primary gastrointestinal stromal tumor (GIST) as a prognostic marker. The aim of the current study was to compare serum midkine (S-MK) concentrations of GIST patients with those of healthy controls and to determine if MK can serve as a prognostic serum marker for these patients.

M3 - SCORING: Journal article

VL - 18

SP - 559

EP - 565

JO - ANN SURG ONCOL

JF - ANN SURG ONCOL

SN - 1068-9265

IS - 2

M1 - 2

ER -